Occult hepatitis B (OBH) in clinical settings

Hepatitis Monthly

Volumn 12, Issue 8, 2012, Pages

  Alavian, Seyed Moayed ^a   Miri, Seyed Mohammad ^a   Hollinger, F Blaine ^b   Jazayeri, Seyed Mohammad ^c  

^a BAQIYATALLAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Coinfection; Hepatitis B; Hepatitis B surface antigens

Indexed keywords

ALEMTUZUMAB; ALKYLATING AGENT; ALPHA INTERFERON RECEPTOR; AMINOTRANSFERASE; ANTIMETABOLITE; ANTINEOPLASTIC ANTIBIOTIC; CORTICOSTEROID; CYTOTOXIC AGENT; HEPATITIS B (E) ANTIBODY; HEPATITIS B SURFACE ANTIGEN; INFLIXIMAB; LAMIVUDINE; MESSENGER RNA; RITUXIMAB; TENOFOVIR; UNCLASSIFIED DRUG; VIRUS DNA; VIRUS RNA;

BLOOD TRANSFUSION; CROHN DISEASE; DISEASE EXACERBATION; DRUG WITHDRAWAL; HEMODIALYSIS PATIENT; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MIXED INFECTION; NONHUMAN; OCCULT HEPATITIS B; PREVALENCE; REVIEW; VIRUS REACTIVATION;

EID: 84874047239     PISSN: 1735143X     EISSN: 17353408     Source Type: Journal    
DOI: 10.5812/hepatmon.6126     Document Type: Review

References (102)

1. Alavian SM, Jazayeri SM. Other views of occult hepatitis B in Hepatitis C infected patients. Eur J Intern Med. 2011;22(5):e67-8.
2. Habibollahi P, Safari S, Daryani NE, Alavian SM. Occult hepatitis B infection and its possible impact on chronic hepatitis C virus infection. Saudi J Gastroenterol. 2009;15(4):220-4.
3. Ramezani A, Banifazl M, Mohraz M, Rasoolinejad M, Aghakhani A. Occult hepatitis B virus infection: A major concern in HIV-infected patients. Hepat Mon. 2011;11(1):7-10.
4. Alavian SM, Nematizadeh F. Occult HBV infection in patients with serological markers of past HBV infection. Am J Gastroenterol. 2003;98(4):937-8.
5. Hollinger FB, Habibollahi P, Daneshmand A, Alavian SM. Occult Hepatitis B Infection in Chronic Hemodialysis Patients: Current Concepts and Strategy. Hepat Mon. 2010;10(3):199-204.
6. Honarkar Z, Alavian SM, Samiee S, Saeedfar K, Baladast M, Ehsani MJ, et al. Occult Hepatitis B as a cause of cryptogenic cirrhosis. Hepat Mon. 2004;4(8):155-60.
7. Hollinger FB. Hepatitis B virus infection and transfusion medicine: science and the occult. Transfusion. 2008;48(5):1001-26.
8. Mosley JW, Stevens CE, Aach RD, Hollinger FB, Mimms LT, Solomon LR, et al. Donor screening for antibody to hepatitis B core antigen and hepatitis B virus infection in transfusion recipients. Transfusion. 1995;35(1):5-12.
9. Chazouilleres O, Mamish D, Kim M, Carey K, Ferrell L, Roberts JP, et al. "Occult" hepatitis B virus as source of infection in liver transplant recipients. Lancet. 1994;343(8890):142-6.
10. Allain JP, Hewitt PE, Tedder RS, Williamson LM. Evidence that anti-HBc but not HBV DNA testing may prevent some HBV trans-mission by transfusion. Br J Haematol. 1999;107(1):186-95.
11. Kleinman SH, Strong DM, Tegtmeier GG, Holland PV, Gorlin JB, Cousins C, et al. Hepatitis B virus (HBV) DNA screening of blood donations in minipools with the COBAS AmpliScreen HBV test. Transfusion. 2005;45(8):1247-57.
12. Chevrier MC, St-Louis M, Perreault J, Caron B, Castilloux C, Laroche J, et al. Detection and characterization of hepatitis B virus of anti-hepatitis B core antigen-reactive blood donors in Quebec with an in-house nucleic acid testing assay. Transfusion. 2007;47(10):1794-802.
13. Kleinman SH, Kuhns MC, Todd DS, Glynn SA, McNamara A, Di-Marco A, et al. Frequency of HBV DNA detection in US blood donors testing positive for the presence of anti-HBc: implications for transfusion transmission and donor screening. Transfusion. 2003;43(6):696-704.
14. Liu Y, Li P, Li C, Zhou J, Wu C, Zhou YH. Detection of hepatitis B virus DNA among accepted blood donors in Nanjing, China. Virol J. 2010;7:193.
15. Yuen MF, Ka-Ho Wong D, Lee CK, Tanaka Y, Allain JP, Fung J, et al. Transmissibility of Hepatitis B Virus (HBV) Infection through Blood Transfusion from Blood Donors with Occult HBV Infection. Clin Infect Dis. 2011;52(5):624-32.
16. Bhatti FA, Ullah Z, Salamat N, Ayub M, Ghani E. Anti-hepatits B core antigen testing, viral markers, and occult hepatitis B virus infection in Pakistani blood donors: implications for transfusion practice. Transfusion. 2007;47(1):74-9.
17. Satake M, Taira R, Yugi H, Hino S, Kanemitsu K, Ikeda H, et al. Infectivity of blood components with low hepatitis B virus DNA levels identified in a lookback program. Transfusion. 2007;47(7):1197-205.
18. Chen YC, Sheen IS, Chu CM, Liaw YF. Prognosis following spontaneous HBsAg seroclearance in chronic hepatitis B patients with or without concurrent infection. Gastroenterology. 2002;123(4):1084-9.
19. Carman WF, Zanetti AR, Karayiannis P, Waters J, Manzillo G, Tanzi E, et al. Vaccine-induced escape mutant of hepatitis B virus. Lancet. 1990;336(8711):325-9.
20. Ola SO, Otegbayo JA, Odaibo GN, Olaleye DO, Olubuyide IO, Sum-merton CB, et al. Occult HBV infection among a cohort of Nigerian adults. J Infect Dev Ctries. 2009;3(6):442-6.
21. Cacciola I, Pollicino T, Squadrito G, Cerenzia G, Villari D, de Franchis R, et al. Quantification of intrahepatic hepatitis B virus (HBV) DNA in patients with chronic HBV infection. Hepatology. 2000;31(2):507-12.
22. Chemin I, Jeantet D, Kay A, Trepo C. Role of silent hepatitis B virus in chronic hepatitis B surface antigen(-) liver disease. Antiviral Res. 2001;52(2):117-23.
23. Chaudhuri V, Tayal R, Nayak B, Acharya SK, Panda SK. Occult hepatitis B virus infection in chronic liver disease: full-length genome and analysis of mutant surface promoter. Gastroenterology. 2004;127(5):1356-71.
24. Datta S, Banerjee A, Chandra PK, Chowdhury A, Chakravarty R. Genotype, phylogenetic analysis, and transmission pattern of occult hepatitis B virus (HBV) infection in families of asymptomatic HBsAg carriers. J Med Virol. 2006;78(1):53-9.
25. Kumar GT, Kazim SN, Kumar M, Hissar S, Chauhan R, Basir SF, et al. Hepatitis B virus genotypes and hepatitis B surface antigen mutations in family contacts of hepatitis B virus infected patients with occult hepatitis B virus infection. J Gastroenterol Hepatol. 2009;24(4):588-98.
26. Motta-Castro AR, Martins RM, Araujo NM, Niel C, Facholi GB, Lago BV, et al. Molecular epidemiology of hepatitis B virus in an isolated Afro-Brazilian community. Arch Virol. 2008;153(12):2197-205.
27. Teo EK, Ostapowicz G, Hussain M, Lee WM, Fontana RJ, Lok AS. Hepatitis B infection in patients with acute liver failure in the United States. Hepatology. 2001;33(4):972-6.
28. Weinberger KM, Bauer T, Bohm S, Jilg W. High genetic variability of the group-specific a-determinant of hepatitis B virus surface antigen (HBsAg) and the corresponding fragment of the viral polymerase in chronic virus carriers lacking detectable HBsAg in serum. J Gen Virol. 2000;81(Pt 5):1165-74.
29. Wagner AA, Denis F, Weinbreck P, Loustaud V, Autofage F, Rogez S, et al. Serological pattern 'anti-hepatitis B core alone' in HIV or hepatitis C virus-infected patients is not fully explained by hepatitis B surface antigen mutants. AIDS. 2004;18(3):569-71.
30. Liu CJ, Chen PJ, Chen DS. Dual chronic hepatitis B virus and hepatitis C virus infection. Hepatol Int. 2009.
31. Sagnelli E, Imparato M, Coppola N, Pisapia R, Sagnelli C, Messina V, et al. Diagnosis and clinical impact of occult hepatitis B infection in patients with biopsy proven chronic hepatitis C: a multicenter study. J Med Virol. 2008;80(9):1547-53.
32. Giannini E, Ceppa P, Botta F, Fasoli A, Romagnoli P, Ansaldi F, et al. Previous hepatitis B virus infection is associated with worse disease stage and occult hepatitis B virus infection has low prevalence and pathogenicity in hepatitis C virus-positive patients. Liver Int. 2003;23(1):12-8.
33. Brechot C, Jaffredo F, Lagorce D, Gerken G, Meyer zum Buschenfelde K, Papakonstontinou A, et al. Impact of HBV, HCV and GBV-C/HGV on hepatocellular carcinomas in Europe: results of a European concerted action. J Hepatol. 1998;29(2):173-83.
34. Cacciola I, Pollicino T, Squadrito G, Cerenzia G, Orlando ME, Raimondo G. Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease. N Engl J Med. 1999;341(1):22-6.
35. Torbenson M, Thomas DL. Occult hepatitis B. Lancet Infect Dis. 2002;2(8):479-86.
36. Pollicino T, Squadrito G, Cerenzia G, Cacciola I, Raffa G, Craxi A, et al. Hepatitis B virus maintains its pro-oncogenic properties in the case of occult HBV infection. Gastroenterology. 2004;126(1):102-10.
37. Minuk GY, Sun DF, Uhanova J, Zhang M, Caouette S, Nicolle LE, et al. Occult hepatitis B virus infection in a North American community-based population. J Hepatol. 2005;42(4):480-5.
38. Raimondo G. Occult hepatitis B virus infection and liver disease: fact or fiction? J Hepatol. 2001;34(3):471-3.
39. Cooper C, Kilby D. Clinical significance of hepatitis B core anti-body positivity in HCV-infected and HCV/HIV coinfected individuals. Clin Infect Dis. 2004;38(9):1335-7.
40. Selim HS, Abou-Donia HA, Taha HA, El Azab GI, Bakry AF. Role of occult hepatitis B virus in chronic hepatitis C patients with flare of liver enzymes. Eur J Intern Med. 2011;22(2):187-90.
41. Toyoda H, Kumada T, Kaneoka Y, Murakami Y. Impact of hepatitis B virus (HBV) X gene integration in liver tissue on hepatocellular carcinoma development in serologically HBV-negative chronic hepatitis C patients. J Hepatol. 2008;48(1):43-50.
42. Sagnelli E, Coppola N, Scolastico C, Mogavero AR, Filippini P, Piccinino F. HCV genotype and "silent" HBV coinfection: two main risk factors for a more severe liver disease. J Med Virol. 2001;64(3):350-5.
43. Fukuda R, Ishimura N, Hamamoto S, Moritani M, Uchida Y, Ishihara S, et al. Co-infection by serologically-silent hepatitis B virus may contribute to poor interferon response in patients with chronic hepatitis C by down-regulation of type-I interferon receptor gene expression in the liver. J Med Virol. 2001;63(3):220-7.
44. Mrani S, Chemin I, Menouar K, Guillaud O, Pradat P, Borghi G, et al. Occult HBV infection may represent a major risk factor of nonresponse to antiviral therapy of chronic hepatitis C. J Med Virol. 2007;79(8):1075-81.
45. Raimondo G, Allain JP, Brunetto MR, Buendia MA, Chen DS, Colombo M, et al. Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepatol. 2008;49(4):652-7.
46. Mphahlele MJ, Lukhwareni A, Burnett RJ, Moropeng LM, Ngobeni JM. High risk of occult hepatitis B virus infection in HIV-positive patients from South Africa. J Clin Virol. 2006;35(1):14-20.
47. Gupta S, Singh S. Occult hepatitis B virus infection in ART-naïve HIV-infected patients seen at a tertiary care centre in north India. BMC Infect Dis. 2010;10:53.
48. Lukhwareni A, Burnett RJ, Selabe SG, Mzileni MO, Mphahlele MJ. Increased detection of HBV DNA in HBsAg-positive and HBsAg-negative South African HIV/AIDS patients enrolling for highly active antiretroviral therapy at a Tertiary Hospital. J Med Virol. 2009;81(3):406-12.
49. Hofer M, Joller-Jemelka HI, Grob PJ, Luthy R, Opravil M. Frequent chronic hepatitis B virus infection in HIV-infected patients positive for antibody to hepatitis B core antigen only. Swiss HIV Cohort Study. Eur J Clin Microbiol Infect Dis. 1998;17(1):6-13.
50. Rodriguez-Torres M, Gonzalez-Garcia J, Brau N, Sola R, Moreno S, Rockstroh J, et al. Occult hepatitis B virus infection in the setting of hepatitis C virus (HCV) and human immunodeficiency virus (HIV) co-infection: clinically relevant or a diagnostic problem? J Med Virol. 2007;79(6):694-700.
51. Shire NJ, Rouster SD, Rajicic N, Sherman KE. Occult hepatitis B in HIV-infected patients. J Acquir Immune Defic Syndr. 2004;36(3):869-75.
52. Hu KQ. Occult hepatitis B virus infection and its clinical implications. J Viral Hepat. 2002;9(4):243-57
53. Filippini P, Coppola N, Pisapia R, Scolastico C, Marrocco C, Zaccariello A, et al. Impact of occult hepatitis B virus infection in HIV patients naive for antiretroviral therapy. AIDS. 2006;20(9):1253-60.
54. Morsica G, Ancarani F, Bagaglio S, Maracci M, Cicconi P, Cozzi Lepri A, et al. Occult hepatitis B virus infection in a Cohort of HIV-positive patients: Correlation with hepatitis C virus coinfection, virological and immunological features. Infection. 2009;37(5):445-9.
55. Benhamou Y. Antiretroviral therapy and HIV/hepatitis B virus coinfection. Clin Infect Dis. 2004;38 (Suppl 2):S98-103.
56. Lo Re V, 3rd, Frank I, Gross R, Dockter J, Linnen JM, Giachetti C, et al. Prevalence, risk factors, and outcomes for occult hepatitis B virus infection among HIV-infected patients. J Acquir Immune Defic Syndr. 2007;44(3):315-20.
57. Lo Re V, 3rd, Wertheimer B, Localio AR, Kostman JR, Dockter J, Linnen JM, et al. Incidence of transaminitis among HIV-infected patients with occult hepatitis B. J Clin Virol. 2008;43(1):32-6.
58. Nebbia G, Garcia-Diaz A, Ayliffe U, Smith C, Dervisevic S, Johnson M, et al. Predictors and kinetics of occult hepatitis B virus infection in HIV-infected persons. J Med Virol. 2007;79(10):1464-71.
59. Soriano V, Puoti M, Peters M, Benhamou Y, Sulkowski M, Zoulim F, et al. Care of HIV patients with chronic hepatitis B: updated recommendations from the HIV-Hepatitis B Virus International Panel. AIDS. 2008;22(12):1399-410.
60. Fang Y, Teng X, Xu WZ, Li D, Zhao HW, Fu LJ, et al. Molecular characterization and functional analysis of occult hepatitis B virus infection in Chinese patients infected with genotype C. J Med Virol. 2009;81(5):826-35.
61. Chan HL, Tsang SW, Leung NW, Tse CH, Hui Y, Tam JS, et al. Occult HBV infection in cryptogenic liver cirrhosis in an area with high prevalence of HBV infection. Am J Gastroenterol. 2002;97(5):1211-5.
62. Hou J, Wang Z, Cheng J, Lin Y, Lau GK, Sun J, et al. Prevalence of naturally occurring surface gene variants of hepatitis B virus in nonimmunized surface antigen-negative Chinese carriers. Hepatology. 2001;34(5):1027-34.
63. Al-Mahtab M, Rahman S, Khan M. Occult Hepatitis B Virus Related Decompensated Cirrhosis of Liver in Young Males: First Report of Two Cases from Bangladesh. Hepat Mon. 2008;8(2):147-50.
64. Brechot C, Thiers V, Kremsdorf D, Nalpas B, Pol S, Paterlini-Brechot P. Persistent hepatitis B virus infection in subjects without hepatitis B surface antigen: clinically significant or purely "occult"? Hepatology. 2001;34(1):194-203.
65. Ikeda K, Marusawa H, Osaki Y, Nakamura T, Kitajima N, Yamashita Y, et al. Antibody to hepatitis B core antigen and risk for hepatitis C-related hepatocellular carcinoma: a prospective study. Ann Intern Med. 2007;146(9):649-56.
66. Raimondo G, Navarra G, Mondello S, Costantino L, Colloredo G, Cucinotta E, et al. Occult hepatitis B virus in liver tissue of individuals without hepatic disease. J Hepatol. 2008;48(5):743-6.
67. Shiota G, Oyama K, Udagawa A, Tanaka K, Nomi T, Kitamura A, et al. Occult hepatitis B virus infection in HBs antigen-negative hepatocellular carcinoma in a Japanese population: involvement of HBx and p53. J Med Virol. 2000;62(2):151-8.
68. Chen CH, Changchien CS, Lee CM, Tung WC, Hung CH, Hu TH, et al. A study on sequence variations in pre-S/surface, X and enhancer II/core promoter/precore regions of occult hepatitis B virus in non-B, non-C hepatocellular carcinoma patients in Taiwan. Int J Cancer. 2009;125(3):621-9.
69. Paterlini P, Driss F, Nalpas B, Pisi E, Franco D, Berthelot P, et al. Persistence of hepatitis B and hepatitis C viral genomes in primary liver cancers from HBsAg-negative patients: a study of a low-endemic area. Hepatology. 1993;17(1):20-9.
70. Michalak TI, Pardoe IU, Coffin CS, Churchill ND, Freake DS, Smith P, et al. Occult lifelong persistence of infectious hepadnavirus and residual liver inflammation in woodchucks convalescent from acute viral hepatitis. Hepatology. 1999;29(3):928-38.
71. Korba BE, Wells FV, Baldwin B, Cote PJ, Tennant BC, Popper H, et al. Hepatocellular carcinoma in woodchuck hepatitis virus-infected woodchucks: presence of viral DNA in tumor tissue from chronic carriers and animals serologically recovered from acute infections. Hepatology. 1989;9(3):461-70.
72. Miura Y, Shibuya A, Adachi S, Takeuchi A, Tsuchihashi T, Nakazawa T, et al. Occult hepatitis B virus infection as a risk factor for hepatocellular carcinoma in patients with chronic hepatitis C in whom viral eradication fails. Hepatol Res. 2008;38(6):546-56.
73. Squadrito G, Pollicino T, Cacciola I, Caccamo G, Villari D, La Masa T, et al. Occult hepatitis B virus infection is associated with the development of hepatocellular carcinoma in chronic hepatitis C patients. Cancer. 2006;106(6):1326-30.
74. Hasegawa I, Orito E, Tanaka Y, Hirashima N, Sakakibara K, Sakurai M, et al. Impact of occult hepatitis B virus infection on efficacy and prognosis of interferon-alpha therapy for patients with chronic hepatitis C. Liver Int. 2005;25(2):247-53.
75. Pollicino T, Raffa G, Costantino L, Lisa A, Campello C, Squadrito G, et al. Molecular and functional analysis of occult hepatitis B virus isolates from patients with hepatocellular carcinoma. Hepatology. 2007;45(2):277-85.
76. Chen BF, Liu CJ, Jow GM, Chen PJ, Kao JH, Chen DS. High prevalence and mapping of pre-S deletion in hepatitis B virus carriers with progressive liver diseases. Gastroenterology. 2006;130(4):1153-68.
77. Kusakabe A, Tanaka Y, Orito E, Sugauchi F, Kurbanov F, Sakamoto T, et al. A weak association between occult HBV infection and non-B non-C hepatocellular carcinoma in Japan. J Gastroenterol. 2007;42(4):298-305.
78. Tamori A, Nishiguchi S, Kubo S, Enomoto M, Koh N, Takeda T, et al. Sequencing of human-viral DNA junctions in hepatocellular carcinoma from patients with HCV and occult HBV infection. J Med Virol. 2003;69(4):475-81.
79. Cortelezzi A, Vigano M, Zilioli VR, Fantini NN, Pasquini MC, Deliliers GL, et al. Adefovir added to lamivudine for hepatitis B recurrent infection in refractory B-cell chronic lymphocytic leukemia on prolonged therapy with Campath-1H. J Clin Virol. 2006;35(4):467-9.
80. Chen MH, Hsiao LT, Chiou TJ, Liu JH, Gau JP, Teng HW, et al. High prevalence of occult hepatitis B virus infection in patients with B cell non-Hodgkin's lymphoma. Ann Hematol. 2008;87(6):475-80.
81. Ferraro D, Pizzillo P, Di Marco V, Vultaggio A, Iannitto E, Venezia G, et al. Evaluating the risk of hepatitis B reactivation in patients with haematological malignancies: is the serum hepatitis B virus profile reliable? Liver Int. 2009;29(8):1171-7.
82. Fukushima N, Mizuta T, Tanaka M, Yokoo M, Ide M, Hisatomi T, et al. Retrospective and prospective studies of hepatitis B virus reactivation in malignant lymphoma with occult HBV carrier. Ann Oncol. 2009;20(12):2013-7.
83. Hui CK, Cheung WW, Zhang HY, Au WY, Yueng YH, Leung AY, et al. Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy. Gastroenterology. 2006;131(1):59-68.
84. Cheung WI, Chan HL, Leung VK, Tse CH, Fung K, Lin SY, et al. Reactivation of hepatitis B virus infection with persistently negative HBsAg on three HBsAg assays in a lymphoma patient undergoing chemotherapy. J Clin Virol. 2010;47(2):193-5.
85. Zhang B, Wang J, Xu W, Wang L, Ni W. Fatal reactivation of occult hepatitis B virus infection after rituximab and chemother-apy in lymphoma: necessity of antiviral prophylaxis. Onkologie. 2010;33(10):537-9.
86. Hui CK, Cheung WW, Leung KW, Cheng VC, Tang BS, Li IW, et al. Retracted: outcome and immune reconstitution of HBV-specific immunity in patients with reactivation of occult HBV infection after alemtuzumab-containing chemotherapy regimen. Hepatology. 2008;48(2):1-10.
87. Iannitto E, Minardi V, Calvaruso G, Mule A, Ammatuna E, Di Trapani R, et al. Hepatitis B virus reactivation and alemtuzumab therapy. Eur J Haematol. 2005;74(3):254-8.
88. Chung SJ, Kim JK, Park MC, Park YB, Lee SK. Reactivation of hepatitis B viral infection in inactive HBsAg carriers following anti-tumor necrosis factor-alpha therapy. J Rheumatol. 2009;36(11):2416-20.
89. Wendling D, Di Martino V, Prati C, Toussirot E, Herbein G. Spondy-loarthropathy and chronic B hepatitis. Effect of anti-TNF therapy. Joint Bone Spine. 2009;76(3):308-11.
90. Grumayer ER, Panzer S, Ferenci P, Gadner H. Recurrence of hepatitis B in children with serologic evidence of past hepatitis B virus infection undergoing antileukemic chemotherapy. J Hepatol. 1989;8(2):232-5.
91. Xunrong L, Yan AW, Liang R, Lau GK. Hepatitis B virus (HBV) reactivation after cytotoxic or immunosuppressive therapy--pathogenesis and management. Rev Med Virol. 2001;11(5):287-99.
92. Angus PW. Review: hepatitis B and liver transplantation. J Gastro-enterol Hepatol. 1997;12(3):217-23.
93. Ghisetti V, Marzano A, Zamboni F, Barbui A, Franchello A Gaia, et al. Occult hepatitis B virus infection in HBsAg negative patients undergoing liver transplantation: clinical significance. Liver Transpl. 2004;10(3):356-62.
94. Uemoto S, Sugiyama K, Marusawa H, Inomata Y, Asonuma K, Egawa H, et al. Transmission of hepatitis B virus from hepatitis B core antibody-positive donors in living related liver transplants. Transplantation. 1998;65(4):494-9.
95. Prieto M, Gomez MD, Berenguer M, Cordoba J, Rayon JM, Pastor M, et al. De novo hepatitis B after liver transplantation from hepatitis B core antibody-positive donors in an area with high prevalence of anti-HBc positivity in the donor population. Liver Transpl. 2001;7(1):51-8.
96. Hussain M, Soldevila-Pico C, Emre S, Luketic V, Lok AS. Presence of intrahepatic (total and ccc) HBV DNA is not predictive of HBV recurrence after liver transplantation. Liver Transpl. 2007;13(8):1137-44.
97. Roche B, Feray C, Gigou M, Roque-Afonso AM, Arulnaden JL, Delvart V, et al. HBV DNA persistence 10 years after liver transplantation despite successful anti-HBS passive immunoprophylaxis. Hepatology. 2003;38(1):86-95.
98. Shetty K, Hussain M, Nei L, Reddy KR, Lok AS. Prevalence and significance of occult hepatitis B in a liver transplant population with chronic hepatitis C. Liver Transpl. 2008;14(4):534-40.
99. Ciesek S, Helfritz FA, Lehmann U, Becker T, Strassburg CP, Neipp M, et al. Persistence of occult hepatitis B after removal of the hepatitis B virus-infected liver. J Infect Dis. 2008;197(3):355-60.
100. Kempinska A, Kwak EJ, Angel JB. Reactivation of hepatitis B infection following allogeneic bone marrow transplantation in a hepatitis B-immune patient: case report and review of the literature. Clin Infect Dis. 2005;41(9):1277-82.
101. Lau GK. Hepatitis B reactivation after chemotherapy: two decades of clinical research. Hepatol Int. 2008;2(2):152-62
102. Werle-Lapostolle B, Bowden S, Locarnini S, Wursthorn K, Petersen J, Lau G, et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology. 2004;126(7):1750-8.